Verici Dx, the next generation, immuno-diagnostics firm is set to transform the success/acceptance rates of kidney transplants. In turn, providing huge benefits for patients, doctors/clinicians, hospitals and healthcare authorities worldwide.
CEO, Sara Barrington, provides an update on the business’ major developments since listing in November, along with explaining the key milestones ahead, specifically in terms of clinical validation, ‘building the foundations’ and full commercialisation.
